In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan
JAC-Antimicrobial Resistance · 30.04.2026 · 8 (3)
DOI: 10.1093/jacamr/dlag096 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 03.06.2026. Verfasst von Katsunori Yanagihara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Meiji Seika Pharma Co., Ltd..
Abstract (Originalsprache)
Objectives
Nacubactam is a novel diazabicyclooctane carbapenemase inhibitor that, in combination with cefepime or aztreonam, has been submitted for regulatory approval in Japan for treating serious Gram-negative infections. This study aimed to evaluate the in vitro activity of nacubactam combined with cefepime or aztreonam against a nationwide collection of clinical carbapenem-resistant Enterobacterales (CRE) isolates in Japan.
Methods
Minimum inhibitory concentration (MIC) values of 376 CRE isolates from 6 medical institutions in Japan were determined according to the Clinical and Laboratory Standards Institute (CLSI) methods. Results were interpreted using clinical breakpoints of the CLSI document M100 (2025) and the European Committee on Antimicrobial Susceptibility Testing clinical breakpoints, version 15.0 (2025).
Results
The predominant CRE isolates were Klebsiella pneumoniae (n = 98), Klebsiella aerogenes (n = 62) and Escherichia coli (n = 43), with the Enterobacter cloacae complex accounting for 117 isolates. Carbapenemase-producing Enterobacterales (CPE) accounted for 48.9% (n = 184), with the predominant carbapenemases being IMP-1 (n = 70), IMP-6 (n = 43) and NDM (n = 17). Cefepime–nacubactam and aztreonam–nacubactam exhibited potent antibacterial activity against CRE isolates with MIC50/90 of 1/4 and 0.5/2 mg/L, respectively. Cefepime–nacubactam and aztreonam–nacubactam demonstrated potent activity against CPE, with MIC50/90 of 2/4 and 0.5/2 mg/L, respectively, which were lower than those for ceftazidime–avibactam (64/>64 mg/L) and imipenem–relebactam (2/16 mg/L). Both combinations exhibited potent antibacterial activity against non-carbapenemase-producing carbapenem-resistant Enterobacterales (non-CP-CRE), with MIC50/90 of 0.25/4 and 0.5/4 mg/L, respectively.
Conclusions
Cefepime–nacubactam and aztreonam–nacubactam have excellent antibacterial activities against CPE and non-CP-CRE, supporting their potential as therapeutic options for CRE infections.
Autor:innen und Institutionen
- Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.
- Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan.
- Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan.
ORCID-Profile: Hayato Okade
Förderung
- Meiji Seika Pharma Co., Ltd.
Zitieren
APA
Yanagihara, K., Tateda, K., Doi, Y., Takahashi, S., Ohge, H., Itahashi, K., Okade, H., & Mikamo, H. (2026). In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan. JAC-Antimicrobial Resistance, 8(3). https://doi.org/10.1093/jacamr/dlag096
Vancouver
Yanagihara K, Tateda K, Doi Y, Takahashi S, Ohge H, Itahashi K, et al. In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan. JAC-Antimicrobial Resistance. 2026;8(3). doi:10.1093/jacamr/dlag096
BibTeX
@article{Yanagihara2026,
author = {Yanagihara, Katsunori and Tateda, Kazuhiro and Doi, Yohei and Takahashi, Satoshi and Ohge, Hiroki and Itahashi, Koju and Okade, Hayato and Mikamo, Hiroshige},
title = {In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {3},
doi = {10.1093/jacamr/dlag096}
}
EUVIMED